Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
KURA has been the subject of several other reports. Oppenheimer set a $18.00 target price on Kura Oncology and gave the company a “buy” rating in a report on Thursday, November 16th. BidaskClub raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Cann reissued a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Wedbush assumed coverage on Kura Oncology in a report on Tuesday, December 26th. They set a “buy” rating and a $19.00 price objective for the company. Finally, ValuEngine lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Kura Oncology presently has a consensus rating of “Buy” and an average target price of $18.08.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). equities research analysts anticipate that Kura Oncology will post -1.52 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in shares of Kura Oncology in the third quarter worth $802,000. Alethea Capital Management LLC boosted its holdings in shares of Kura Oncology by 15.5% in the third quarter. Alethea Capital Management LLC now owns 111,673 shares of the company’s stock worth $1,670,000 after acquiring an additional 15,000 shares during the period. EAM Investors LLC bought a new position in shares of Kura Oncology in the third quarter worth $2,884,000. TIAA CREF Investment Management LLC bought a new position in shares of Kura Oncology in the second quarter worth $385,000. Finally, Artal Group S.A. bought a new position in shares of Kura Oncology in the third quarter worth $1,495,000. 62.96% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Kura Oncology (KURA) Upgraded by Zacks Investment Research to Hold” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/08/kura-oncology-kura-upgraded-by-zacks-investment-research-to-hold.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.